Informação sobre produto
- Dihydroprostaglandin E1Dihydro-pge1
- (11alpha,15S)-11,15-dihydroxy-9-oxoprostan-1-oic acid
- (11α,15S)-11,15-Dihydroxy-9-oxoprostan-1-oic acid
- (15S)-Dihydroprostaglandin E<sub>1</sub>
- 11,15-Dihydroxy-9-ketoprostanoic acid
- 11α,15-Dihydroxy-9-oxoprostanoic acid
- 13,14-Dihydro-PGE<sub>1</sub>
- 13,14-Dihydroprostaglandin E<sub>1</sub>
- 13,14-Dihydroprostaglandinee1
- 13,14-dihydro PGE1
- Ver mais sinónimos
- 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
- 9-Oxo-11Alpha,15S-Dihydroxy-Prostan-1-Oic Acid
- Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxyoctyl)-5-oxo-, stereoisomer
- Dihydro-PGE<sub>1</sub>
- Dihydroprostaglandin E<sub>1</sub>
- PGE<sub>0</sub>
- Pge0
- Prostaglandin E<sub>0</sub>
- Prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,15S)-
- U 23307
Prostaglandin E0 is a potent vasodilator that is synthesized by cyclooxygenase (COX) enzymes. It is used as a drug for the prevention of myocardial infarct, as well as for the treatment of chronic heart failure patients. Prostaglandin E0 also has clinical relevance in occlusive diseases such as angina pectoris, peripheral vascular disease, and Raynaud’s phenomenon. The prostaglandin receptor binding site in the human liver has been identified with hydroxyl group containing fatty acids. A two-way crossover study demonstrated the efficacy of prostaglandin E0 on muscle cell proliferation in an experimental model. Prostaglandin E0 can be used to regulate blood flow and reduce vascular resistance in patients with occlusive vascular disease, or who are at risk for thrombosis.
Propriedades químicas
Consulta técnica sobre: 3D-BP179596 Prostaglandin E0
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
